The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | A-HIPI, a novel prognostic model for advanced HL & outcomes of elderly patients with HL in Australia
Eliza Hawkes, FRACP, MD, MBBS, Austin Health, Melbourne, Australia, comments on the development and validation of a novel prognostic system for advanced Hodgkin lymphoma (HL), A-HIPI (advanced-stage HL international prognostication index), and describes the results of a study evaluating the characteristics and outcomes of elderly patients with classical HL in Australia. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Regeneron: Speakers Bureau; Janssen: Speakers Bureau; Astra Zeneca: Speakers Bureau; Merck Sharpe and Dohme: Membership on an entity’s Board of Directors or advisory committees; Roche: Membership on an entity’s Board of Directors or advisory committees; Bristol_Myers Squibb: Membership on an entity’s Board of Directors or advisory committees; Astra Zeneca: Research Funding; Merck KgA: Research Funding; Bristol-Myers Squibb: Research Funding; Roche: Research Funding; Roche: Speakers Bureau; Gilead: Membership on an entity’s Board of Directors or advisory committees; Antengene: Membership on an entity’s Board of Directors or advisory committees; Link: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees; Beigene: Membership on an entity’s Board of Directors or advisory committees; Specialised Therapeutics: Consultancy.
